ALTAFLUOR BENOX (fluorescein sodium and benoxinate hydrochloride) by Engine Biosciences is 12. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ALTAFLUOR BENOX is a fixed-combination ophthalmic solution containing fluorescein sodium (disclosing agent) and benoxinate hydrochloride (rapid-acting ester anesthetic). It provides corneal anesthesia within 5-45 seconds with a duration of approximately 20 minutes, suitable for diagnostic and minor ophthalmic procedures. The product combines visualization and anesthesia in a single application.
Product is at peak commercial maturity with moderate competitive pressure (30% intensity), indicating a stable but competitive market environment requiring sustained brand management.
12. CLINICAL PHARMACOLOGY This product is the combination of a disclosing agent with a rapidly acting ester anesthetic of short duration. 12. 2 Pharmacodynamics Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Engine Biosciences is hiring 4 roles related to this product
Worked on ALTAFLUOR BENOX at Engine Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ALTAFLUOR BENOX offers exposure to ophthalmic pharmaceuticals and niche specialty care markets. The peak-stage product provides opportunities in brand management, medical affairs, and clinical support roles, though limited job openings (1 linked position) suggest a smaller team and focused career track.
1 open roles linked to this drug